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Acute heart failure (HF) is themost commondiagnosis at discharge in patients aged N65 years. It carries a dismal
prognosiswith a high in-hospitalmortality and very highpost-dischargemortality and re-hospitalization rates. It
is a complex clinical syndrome that cannot be described as a single entity as it varies widely with respect to
underlying pathophysiologicmechanisms, clinical presentations and, likely, treatments. It is the aim of this paper
todescribe someof themain clinical presentations of acuteHF. Amongst them,wewill considerdenovoHFversus
acutely decompensated chronic HF, HF caused, and/or worsened, by myocardial ischemia, acute HF with low,
normal, or high systolic blood pressure, acute HF caused by lung congestion or ﬂuid retention or ﬂuid
redistribution to the lungs, and acuteHFwith comorbidities (diabetes, anemia, renal insufﬁciency, etc.). Different
pathophysiologic mechanisms and clinical presentations may coexist in the same patient. Identiﬁcation and,
whenever possible, treatment of underlying pathophysiologic mechanismsmay become important for acute HF
management.
© 2010 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Acute heart failure (HF) is the most common diagnosis at discharge
in patients aged N65 years. It carries a dismal prognosis with an in-
hospitalmortality rate of 3–8%, a 60–90 daymortality rate of 9–13%, and
a short-term re-hospitalization rate of 25–30% [1–7]. Acute HF is a
complex clinical syndrome that may vary widely with respect to
underlying pathophysiologic mechanisms and clinical presentations
and, as such, it resists straightforward deﬁnition and classiﬁcation. A
cardiac cause of symptoms and urgency of care are, however, present in
all the forms of acute HF and, thus, despite some controversies [8], this
deﬁnition maintains its validity.
Treatment of acute HF remains amajor challenge of current clinical
practice and the heterogeneity of acute HF is likely one of the major
causes of these difﬁculties. It is highly unlikely that a single treatment
algorithm may be feasible for all the patients with acute HF. At
present, we lack sufﬁcient tools to identify different pathophysiologic
mechanisms (i.e. hemodynamic abnormalities, myocardial ischemia,
renal dysfunction, neurohormonal activation, inﬂammation, etc.) and
to target treatment accordingly.
We will herein describe some of the more common clinical
scenarios of acute HF and highlight their implications with regards
pathophysiology and treatment. It is our belief that treatment of acute
HF directed at speciﬁc pathologic targets may inﬂuence both in-
hospital and post-discharge outcomes.
2. Clinical scenarios in European guidelines
According to the 2005 European Society of Cardiology (ESC)
guidelines on acute HF [9] and the more recent ESC HF guidelines [8],
acuteHF is deﬁnedas “a rapidonset or change in the signsandsymptoms
of HF, resulting in the need for urgent therapy.” These guidelines then
point out the heterogeneity of this syndrome indicating that it may be
either new onset HF or worsening of pre-existing HF and that cardiac
dysfunctionmay be related to different causes, including acute coronary
syndromes (ACS), valve dysfunction, arrhythmias, pericardial disease,
and increased left ventricular (LV) afterload and that these different
causes may interact [1,8,9].
The potential clinical presentations of acute HF have been
classiﬁed in the ESC guidelines (Table 1) [8]. Amongst the 3580
patients with acute HF enrolled in the recent EuroHeart Failure Survey
(EHFS) II, by adopting the aforementioned classiﬁcation, 2340 (65.4%)
presented with decompensated HF, 407 (11.4%) with hypertensive
HF, 581 (16.2%) with pulmonary oedema, 139 (3.9%) with cardiogenic
shock, and 113 (3.2%)with isolated right HF [4]. In this review, wewill
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describe some clinical factors which may inﬂuence and cause these
clinical presentations. Importantly, more than one factor may coexist
in the same patient.
3. De novo acute heart failure versus decompensation of chronic
heart failure
Acute decompensatedHFmay present either as new onset (de novo)
HF, i.e. as ﬁrst manifestation of cardiac disease, or as decompensation of
chronic HF (ADCHF) and these two forms differ. Data from the EHFS II
indicate that, when compared to ADCHF subjects, patients with de novo
acuteHFmore frequently presentwith acute pulmonary edema (26% vs.
10.4%) and cardiogenic shock (6.8% vs. 2.2%), are hypertensive on
admission, and are more likely to have an acute coronary syndrome
(ACS) as a precipitating factor (42% vs. 23%) [4]. Patients with de novo
acute HF are, however, less likely to have a history of prior myocardial
infarction (MI) aswell as comorbidities (diabetesmellitus, renal failure,
chronic obstructive pulmonary disease, and anemia). Consistent results
have been also observed in the Italian Acute Heart Failure Survey [3].
With respect to prognosis, short-term mortality data do not
substantiallydiffer among these twoclinical proﬁles. In-hospitalmortality
appears to be similar [3] or higher (8.1% vs. 5.8% in the EHFS II) [4] in
subjects with de novo acute HF, most likely because of the higher
prevalence of cardiogenic shock in such patients. In the Acute Decom-
pensated Heart Failure National Registry (ADHERE) a previous history of
chronic HF was not shown to be an independent predictor of in-hospital
mortality [10].
Post-discharge prognosis appears to be better in patientswith de novo
acuteHF and this trend is likelydue, at least partially, to themore frequent
presence of reversible causes (ACS, hypertension, etc.) and to the lower
prevalence of comorbid conditions in the patients with new onset HF
compared to those with ADCHF. In the Italian registry, post-discharge
mortality at 6 months was 8.4% in de novo acute HF patients as compared
to 16.0% in patients with pre-existing chronic HF, and re-hospitalization
rate was slightly lower in the former group (38.1% vs. 41%) [3]. In the
Etude Francaise de l'Insufﬁsance CardiaqueAigue (EFICA), the history of a
prior episode ofworsening HFwas an independent predictor ofmortality
at 1 month from admission in 392 patients without cardiogenic shock,
consistent with a better clinical course in patients with new onset HF [6].
In a cohort of 497 consecutive patients admitted to our institute for acute
HF, 307 (62%) with ADCHF and 190 (38%) with de novo acute HF, we
observed a worse prognosis, with a higher incidence of death and HF re-
hospitalization during amean follow-up of 387 days, in the patients with
ADCHF.
4. Myocardial ischemia and necrosis
Ischemic heart disease is the most common cause of HF in Europe
and in theUnited States. Data from large registries indicate that a history
of ischemic heart disease is present in up to 45–60% of patients admitted
for acute HF. Nearly 40% of patients with acute HF have experienced a
priorMI, the highest prevalence being observed in subjects with ADCHF
[2–6]. Ischemic etiology has been consistently reported as an important
predictor of increased mortality risk in chronic HF [11]. Conversely, in
acute HF, ischemic etiology has not been often found to be an
independent prognostic variable unless when associated with cardio-
genic shock. It is possible that the potential prognostic role of acute
myocardial ischemia may be affected by the use of coronary
revascularization procedures, and that thesemay diminish the negative
effects of ischemia [12].
There are many potential connections between coronary artery
disease and acute. Myocardial ischemia and myocyte necrosis may
constitute either a trigger for acute HF (i.e., ACS leading to HF), or
alternatively the HF event itself may lead to myocardial ischemia or
necrosis in the absence of frank ACS. ACS are the precipitating cause of
acute HF in 20–30% of patients, mainly in de novo acute HF patients. The
role of ACS as the pathogenic mechanism of acute HF may vary
according to the clinical scenario being greater in acute pulmonary
edema and cardiogenic shock (Fig. 1) [4]. More speciﬁcally, ST elevation
ACS account for more than half of the cases of cardiogenic shock, the
clinical proﬁle of acute HF associated with the highest in-hospital
mortality rate [4].
On the other hand, myocardial ischemia and necrosis may occur
during an episode of acute HF as a consequence of a transient reduction
in coronary perfusion due to increased left ventricular ﬁlling pressure,
reduced systemic arterial blood pressure, tachycardia, coronary vaso-
constriction and endothelial dysfunction mediated by neurohormonal
activation (angiotensin, norepinephrine, andendothelin), inﬂammatory
mechanisms and platelet activation (Fig. 2) [13]. Subjects with pre-
existing coronary artery disease are particularly vulnerable especially
because of the possible presence of areas of hibernating myocardium,
but ischemia may also occur in patients with non-ischemic cardiomy-
opathy and normal coronary arteries [14,15]. We recently reported an
increase of plasma troponin T to detectable plasma levels, measured
serially after admission for acute HF, in 53% of patients with ischemic
heart disease and in 40% of patients with normal coronary arteries [15].
Table 1





– History of heart failure
– Progressive worsening
– Systemic and pulmonary congestion
Acute pulmonary oedema – Severe dyspnea and orthopnoea
– Pulmonary rales
Hypertensive heart failure – High blood pressure
– Relatively preserved left ventricular function
– Pulmonary edema with or without ﬂuid overload
Cardiogenic shock – Hypotension (systolic blood pressure b90 mm
Hg or a drop of mean arterial pressure N30 mm Hg)
– Absent or low diuresis (b0.5 mL/kg/h)
– Evidence of organ hypoperfusion and pulmonary
congestion
Isolated right HF – Low output syndrome
– Absence of pulmonary congestion and low LV ﬁlling
Pressures
– Increased jugular venous pressure, with or without
hepatomegaly
Associated with acute coronary syndromea
With an arrhythmia Bradycardia, atrial ﬁbrillation, ventricular tachycardia
a Acute HF may be either precipitated by or associated with an acute coronary
syndrome or an arrhythmia.
Fig. 1. Proportion of patients with an acute coronary syndrome as the precipitating
factor of acute heart failure (adapted from Ref. [4]).
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The clinical relevance of myocardial necrosis in heart failure has
been demonstrated by studies based on plasma troponin measure-
ments. An increase of plasma troponin levels has been reported in 40%
to 70% of patients admitted for acute HF [15–17], depending on the
study population and assay utilized. The lower proportion (6.2%) found
in the ADHERE registry, including 84,872 patients with acute HF, may
be related to troponin measurements only at the time of admission
[14].
The increase in cardiac troponins has been shown to be associated
with both a short- and long-term increase in mortality and re-
hospitalization rates [14–16]. In a recent post-hoc analysis from
ADHERE, the increase of troponins (I or T) was found to be associated
to a in-hospital mortality rate of 8% as opposed to 2% in patients with
negative troponins (pb0.001) [14]. We have reported that patients
exhibiting an increase in plasma troponin T in at least one of daily
serial measurements during an acute HF hospitalization had a three-
fold increase in 6 month mortality as compared to patients with no
measurable troponin levels (31% vs. 9%, respectively; pb0.001) [15].
Measurement of plasma troponins may be a useful prognostic index
and a potential surrogate of the effects of medical therapy on
prognosis in patients with acute HF [18].
These ﬁndings regarding myocyte necrosis may have important
implications for the selection of therapies for AHF. The use of agents
with hemodynamic effects (vasodilators and inotropes) may precip-
itate/exacerbate a conditionofmyocardial ischemia andnecrosis.With
the exception of nitrates, usually proven to be safe because of their
selective coronary vasodilating properties, other vasodilators, such as
nitroprusside, nesiritide, and ularitide, may cause excessive arterial
hypotension (along with “coronary steal” in the case of nitroprusside)
with consequent coronary hypoperfusion. Inotropic agents are likely
to cause myocardial damage to an even greater extent by inducing a
signiﬁcant increase in myocardial oxygen consumption and sub-
endocardial ischemia (Fig. 2) [19]. These detrimental effects provide,
at least in part, an explanation for the increased mortality associated
with the early administration of nitroprusside in acuteHF secondary to
a recent AMI [20], and with the use of inotropes in patients with acute
HF of ischemic etiology [21]. Inotrope administration alone [22], or in
combination with vasodilators [23], was shown to be independently
associated with an increased mortality in both ADHERE and in the
Evaluation Study of Congestive Heart Failure and Pulmonary Artery
Catheterization Effectiveness (ESCAPE) study.
5. Systolic blood pressure
The majority of patients admitted for acute HF present with normal
or normal-high values of systolic blood pressure (SBP). Among the
patients enrolled in the large international acute HF registries, a SBP at
admission N140 mm Hg was observed in 45–50%, a SBP of 120 to
140 mm Hg in 40% and only 3–8% of the patients showed SBP b90 mm
Hg [2,3,5].
Elevated SBP during acute HF episodes may have at least two
different pathophysiologic implications: 1) it may be a precipitating
factor of HF through excessive vasoconstriction and increased afterload;
or 2) it may be a consequence of neurohormonal activation and cardiac
stimulation due to acute HF itself. The former is the case of an acute HF
with a mainly vascular, rather than cardiac, pathogenesis, and elevated
SBPbecomes theprincipal target for therapy. This form ismore common
in women and the elderly, as well as in patients with preserved left
ventricular ejection fraction [24–27]. It will be considered in greater
detail in the next section.
Systolic blood pressure is a critical metric for targeting therapy in
patients with acute HF. Patients with high SBP are sensitive to
vasodilator therapy and usually do not need high diuretic doses as
their main mechanism of dyspnea is ﬂuid redistribution to the lungs
rather than ﬂuid accumulation [7–9,26–29]. Conversely, vasodilators
and/or other agents with concomitant vasodilator activity should be
used with extreme caution, if not at all, in patients with normal to low
SBP on admission. In these patients the drop in SBPmay cause a decline
in blood ﬂow to the myocardium or the kidney to critical levels with
secondary organ damage and poor prognosis [7,28]. Excessive
vasodilationwith nesiritide or with levosimendan has been associated
with untoward effects on renal function [30] and prognosis [31,32]. In
recent phase II trials, the administration of new vasodilators such as
relaxin has been attended by favourable effects on prognosis in
patientswith acute HF and SBP N125 mmHgusing restrictive stopping
rules of treatment when excessive SBP drops occurred [33].
6. Fluid overload: accumulation versus redistribution
The vast majority of patients with acute HF present with dyspnea
and evidence of pulmonary and/or systemic congestion [34]. A
progressive gain in body weight [35] and increase in ventricular ﬁlling
pressures [36,37] may begin several days to weeks preceding the
admission for HF. Zile et al. have recently assessed changes in estimated
pulmonary artery diastolic pressure (ePAD) in patients who underwent
implantation of a continuous intracardiac pressure monitoring device.
An increase in ePAD was associated with episodes of acute decom-
pensated HF both in patients with low LV ejection fraction (increase
from 21±9 to 24±8 mm Hg; pb0.05) and in those with normal LV
ejection fraction (increase from 17±7 to 22±7 mm Hg; pb0.05). No
changes occurred in the patients who remained clinically stable.
Thus, increases in pulmonary pressure and pulmonary congestion
are the main mechanism causing dyspnea and, ultimately, the
hospitalization of patients with HF. These changes may, or may not,
occur as a consequence of sodium and water retention and total body
ﬂuid overload. In fact, there are cases in which acute HF may occur
Fig. 2.Mechanisms of myocardial damage in patients with acute heart failure (top) and
potential effects of traditional inotropic agents (bottom).
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without salt and water retention and weight gain and the underlying
mechanism is rather a redistribution of ﬂuids to the lungs with
pulmonary, but not systemic, congestion [24–27].
Vasoconstriction, rather than ﬂuid retention, may play a pivotal
role in these vascular forms of acute HF. Venoconstriction causes an
increase in venous return to the right heart which by interacting with
poorly compliant ventricles leads to a rise in end-diastolic pressures of
both ventricles. Arterial vasoconstriction increases the left ventricular
afterload with a reduction of stroke volume and further increase in
intraventricular pressures. Vasoconstriction, particularly in the pres-
ence of diastolic dysfunction may cause an increase in pulmonary
capillary pressure, pulmonary congestion and oedema. All of the above
mechanisms may take place even in the absence of volume retention
through a redistribution of ﬂuid from the peripheral to the pulmonary
circulation. The mechanisms underlying excessive vasoconstriction
are not fully elucidated, to date, but neurohormonal activation and
inﬂammation may have a central role [38]. A comparison between
these 2 different pathophysiological and clinical proﬁles of acute HF is
proposed in Table 2.
7. Cardiac and non-cardiac comorbidities
The prevalence of comorbidities is high in patients with acute HF
and the most common ones are summarized in Table 3. Cardiac and
non-cardiac conditions may be concomitant to or act as precipitating
factors/triggers of acute HF and signiﬁcantly affect its clinical
manifestations and prognosis. Ischemic heart disease, arrhythmias,
and valvular heart disease were frequent in patients from the EHFS II
and represented each the precipitating factor of nearly one third of the
total cases of acute HF [4].
As for non-cardiac comorbidities, chronic kidney disease has been
reported to be present in 30–35%, chronic obstructive pulmonary
disease in10–30%, diabetesmellitus in35–40%, and anemia in15–20%of
the patients with acute HF. Amongst different comorbidities, renal
dysfunction seems to be the one more likely to play a major role in the
pathogenesis and prognosis of the patients with acute HF. A mild to
moderate impairment of renal dysfunction is present in the majority of
patients with acute HF. Kidney function is highly dependent on the
patient's hemodynamics as demonstrated by studies showing the tight
relation between renal function and both cardiac output and venous
pressure (Fig. 3). The important role of renal venous pressure, in
addition to cardiac output, as a major determinant of renal function has
been recently shown [39–41]. Neurohormonal activation and concom-
itant therapy (namely, diuretics) may also play a major role in the
development of kidney dysfunction in the patients with acute HF.
Multiple studies have shown that renal dysfunction is one of the
most important determinants of prognosis, both in-hospital and post-
discharge, in the patients hospitalized for acute HF [3,4,10,42].
Worsening renal function during hospitalization for acute HF is another
determinant of a poor prognosis. Some degree of worsening renal
function occurs, depending on the speciﬁc deﬁnition applied, in
approximately 30% of the patients with acute HF and is associated
with longer hospital stay, increased in-hospitalmortality, and increased
post-discharge mortality and re-hospitalizations [43,44]. We recently
reported that an increase of N25% and N0.3 mg/dL from admission of
serum creatinine levels is an independent predictor of post-discharge
mortality in patients with acute HF (RR at multi-variable analysis, 1.47;
95% CI, 1.13–1.81; p=0.024). Administration of high doses of
furosemide was among the main determinants of worsening renal
function, although it is impossible to determine fromobservational data
whether this is simply a marker of greater disease severity [45].
Renal dysfunction may contribute to the poor prognosis of the
patients with acute HF through multiple mechanisms. These include
increased neurohormonal activation and inﬂammation, intolerance to
renin–angiotensin–aldosterone antagonists, increasedﬂuid and sodium
retention and resistance to loop diuretics [46]. Similar as with renal
dysfunction, all of the comorbidities listed in Table 3 have been reported
to be associated, generally in an independent fashion, with a worse
prognosis in patients with acute HF and have been included in multi-
Table 2
Comparison between two different clinical and pathophysiological proﬁles of acute
heart failure.a
Vascular (peripheral) Cardiac (central)
Main mechanism of onset ↑ afterload ↓ contractility renal
hypoperfusion
LVEF Normal Low






Onset Rapid (hours) Gradual (days)
Main symptom Dyspnea Fatigue





Systolic BP Normal or high Normal or low
LV ﬁlling pressure High May be reduced by
low CO
Cardiac output Normal or high Low
Mortalityb
In-hospital Low (b5%) High (≥5%)
3-months Relatively low (5–7%) High (10–15%)
3-months
re-hospitalizations
High (30%) High (30%)
a Bothmay coexist in any patient thoughwith a differentmagnitude in each individual.
b Reported survival estimates are to be considered as non-absolute being the mortality
also affectedbyother factors such as, for instance,mean length of hospital stay. BP=blood
pressure; CO= cardiac output; and LVEF = left ventricular ejection fraction.
Table 3




Chronic ischemic cardiac disease
Hypertension
Arrhythmias (atrial ﬁbrillation, etc.)
Valvular disease (mitral regurgitation, etc.)
Non-cardiac
Chronic kidney disease








Fig. 3. Relations between heart failure and kidney dysfunction.
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variable models of risk prediction [47,48]. However, only intervention
studies with drugs selectively targeting these comorbidities will be
powered to deﬁnitely demonstrate whether such conditions directly
contribute to the progression of HF or are just epiphenomena of a more
severe disease state.
8. Conclusions
Patients with acute HF are a heterogeneous population with respect
to both clinical proﬁles at presentation and pathophysiological
mechanisms. Speciﬁc pathophysiologic substrates act as precipitating
or concomitant factors in acute HF and signiﬁcantly affect prognosis and
represent targets for treatment. Treatment tailored to individual clinical
presentations and pathophysiologic mechanisms will be more likely to
improve prognosis of the patients with acute HF.
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